To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

CNW/ -- (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth ...

FDA experts report changes in drug approvals, warnings, and indications for products for use by dermatologists and aesthetic medicine professionals.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

Mosedipimod is under clinical development by Enzychem Lifesciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

ASN-008 is under clinical development by Formation Bio and currently in Phase II for Notalgia Paresthetica. According to GlobalData, Phase II drugs for Notalgia Paresthetica does not have sufficient ...

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...